Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Available until 4/1/2024

Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.

Already Have An Account? Log in Now

story of the week
Published in Oncology

Journal Scan / Research · February 08, 2024

Concomitant Administration of EGFRvIII-Targeted CAR T-Cell Therapy and Pembrolizumab in Adults With Glioblastoma

Nature Cancer

 

TAKE-HOME MESSAGE

abstract

This abstract is available on the publisher's site.

Access this abstract now  

Additional Info

Disclosure statements are available on the authors' profiles:

Nature Cancer
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial
Nat Cancer 2024 Jan 12;[EPub Ahead of Print], SJ Bagley, ZA Binder, L Lamrani, E Marinari, AS Desai, MP Nasrallah, E Maloney, S Brem, RA Lustig, G Kurtz, M Alonso-Basanta, PE Bonté, C Goudot, W Richer, E Piaggio, S Kothari, L Guyonnet, CL Guerin, JJ Waterfall, S Mohan, WT Hwang, OY Tang, M Logun, M Bhattacharyya, K Markowitz, D Delman, A Marshall, EJ Wherry, S Amigorena, GL Beatty, JL Brogdon, E Hexner, D Migliorini, C Alanio, DM O'Rourke

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.


Further Reading